Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Repligen Corp

+ Add to Watchlist

RGEN:US

40.8800 USD 0.3100 0.75%

As of 20:10:00 ET on 05/22/2015.

Snapshot for Repligen Corp (RGEN)

Open: 40.9700 Day's Range: 40.6000 - 41.7100 Volume: 248,668
Previous Close: 41.1900 52wk Range: 18.2300 - 42.4300 1-Yr Rtn: +114.26%

Stock Chart for RGEN

No chart data available.
  • RGEN:US 40.8800
  • 1D
  • 1M
  • 1Y
41.1900
Interactive RGEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RGEN

Current P/E Ratio (ttm) 153.5843
Estimated P/E(12/2015) 123.8788
Relative P/E vs. SPX 8.1753
Earnings Per Share (USD) (ttm) 0.2662
Est. EPS (USD) (12/2015) 0.3300
Est. PEG Ratio -
Market Cap (M USD) 1,343.00
Shares Outstanding (M) 32.85
30 Day Average Volume 421,701
Price/Book (mrq) 11.9981
Price/Sale (ttm) 19.5961
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/11/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RGEN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RGEN

Repligen Corporation is a biotechnology company. The Company develops therapeutics for the treatment of diseases of the central nervous system. Repligen owns owns intellectual property on monoclonal antibody and antibody fusion products.

Tony J HuntPresident/CEOJon K SnodgresChief Financial Officer
James R RuscheSenior VP:Research & DevHoward BenjaminVP:Business Development
More Company Profile & Key Executives for RGEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil